2012年1月15日 · VTX-2337 is a novel small-molecule TLR8 agonist that activates monocytes, DCs, and NK cells. Through the activation of NK cells, it has the potential to augment the effectiveness of monoclonal antibody treatments where …

2017年5月15日 · Motolimod (VTX-2337), a selective small-molecule agonist of TLR8, stimulates natural killer (NK) cells, dendritic cells, and monocytes. A phase Ib clinical trial assessed the safety and antitumor activity of motolimod in combination with cetuximab in patients with SCCHN.

VTX-2337 is a novel, potent and selective small molecule (<500 MW) TLR8 agonist which activates myeloid dendritic cells, monocytes and NK cells to produce chemokines and Th1 polarizing cytokines, including TNFα, IL-12 and IFNγ. Such impacts induce innate and adaptive immune responses against tumor cells.

The role of TLR8 in inflammation and fibrosis was investigated using a TLR8-overexpression vector, activator (VTX-2337), inhibitor (cu-cpt-8m), and TLR8 siRNA in skin fibroblasts. The pathogenic role of TLR8 in skin inflammation and fibrosis was further validated in a bleomycin (BLM)-induced mouse skin inflammation and fibrosis model.

2012年1月16日 · VTX-2337 has been tested in a first-in-man clinical trial evaluating the pharmacokinetics, pharmacodynamic responses as well as safety and tolerability in late-stage oncology patients, and subsequent clinical oncology studies assessing VTX-2337 in combination with mAb therapies or anthracycline chemotherapy have been initiated.

2021年1月15日 · VTX-2337 delayed tumor growth in all 3 syngeneic mouse models and significantly increased the survival of cetuximab-treated mice. The anti-tumor effects of VTX-2337+ cetuximab were accompanied...

Motolimod (VTX-2337;VTX-378) is a selective Toll-like receptor 8 (TLR8) agonist, with an EC 50 of approximately 100 nM.

Motolimod (VTX-2337)是一种选择性且有效的Toll-like receptor 8 (TLR8)激动剂，EC50为100 nM, 比作用于TLR7的选择性高50倍以上。Phase 2。 靶点

2016年2月29日 · VTX-2337 (USAN: motolimod) is a selective toll-like receptor 8 (TLR8) agonist, which is in clinical development as an immunotherapy for multiple oncology indications, including squamous cell carcinoma of the head and neck (SCCHN).

Motolimod（VTX-2337）是Toll样受体（TLR）8的选择性小分子激动剂，EC50值为100 nM[1]。 VTX-2337目前正在临床上研究用作多种肿瘤指征的免疫治疗剂，包括卵巢癌和头颈部鳞状细胞癌[2]。